While these drugs are highly effective for weight loss and glycemic control, they are associated with gastrointestinal issues such as nausea, vomiting, and diarrhea, which can lead to treatment discontinuation among some patients For instance, clinical data and patient reports have shown that adverse events are particularly common during the early stages of treatment with drugs such as semaglutide and tirzepatide, prompting careful dose titration and medical supervision, which may not be feasible for all patients or healthcare settings Addressing these side effect concerns through better patient education, physician training, and next-generation formulations with reduced tolerability issues is crucial to improving long-term adherence and treatment outcomes
Lixisenatide therapy in older patients with type 2 diabetes inadequately controlled on their current antidiabetic treatment: the getgoal-o randomized trial
Aguirre SA, Heyen JR, Collette W, Bobrowski W, Blasi ER (April 2010)
Constipation can occur and should be managed proactively from the first week
Batch-specific reports available on request
